.jpeg)
{{ variable.name }}
Lusutrombopag promotes platelet production and reduces the need for platelet transfusion before surgery by activating TPO receptors on megakaryocytes.
1. Generic name: Rutrombopag
2. Trade name: MULPLETA®
It is used to treat thrombocytopenia in adult patients with chronic liver disease who plan to undergo surgery.
1. Specifications: Each tablet contains 3 mg of Rutrombopag.
2. Characteristics: Light red round film-coated tablet, with Shionogi trademark and code "551" engraved on one side and "3" engraved on the other side.
1. Active ingredient: Rutrombopag.
2. Excipients include: D-mannitol, microcrystalline cellulose, magnesium oxide, sodium lauryl sulfate, hydroxypropyl cellulose, calcium carboxymethylcellulose, magnesium stearate, hypromellose, triethyl citrate, titanium dioxide, red iron oxide, and talc.
1. Recommended dosage: 3 mg once a day, orally, for 7 consecutive days.
2. Timing of administration: Medication should be started 8 to 14 days before planned surgery. Surgery should be performed within 2 to 8 days after the last dose.
3. How to take: It can be taken with food or alone.
No specific dose adjustment scheme for patients with liver and kidney dysfunction is mentioned. Data are limited in patients with severe renal insufficiency or severe hepatic insufficiency and caution should be used.
1. It can be taken before or after meals.
2. If you miss a dose, you should take it as soon as possible on the same day, and resume your normal medication schedule the next day. You should not take a double dose.
3. Platelet count needs to be closely monitored during and after medication to prevent excessive platelet elevation leading to the risk of thrombosis.
4. This drug is only used to increase platelets to a level acceptable for surgery. You should not try to restore the platelet count to normal through medication.
1. Pregnancy period: There is no human data. Animal studies show developmental toxicity. It should be used when the potential benefits outweigh the risks.
2. Breastfeeding: Breastfeeding is not recommended during treatment and for at least 28 days after the last dose.
3. Children: Safety and effectiveness have not been established.
4. Elderly people: Clinical studies have not found any significant difference in response from younger patients.
1. The most common adverse reaction: headache.
2. Serious risks: thrombosis/thromboembolic complications, including portal vein thrombosis.
None.
1. No clinically significant changes in Rutrombopag exposure were observed when used in combination with cyclosporine or antacids containing polyvalent cations.
2. No clinically significant changes in midazolam exposure were observed when used in combination with midazolam.
3. In vitro studies have shown that Rutrombopag is a substrate of P-gp and BCRP, but its inhibitory potential for major CYP enzymes and transporters is low.
1. Store in the original packaging at a temperature of 20°C to 25°C, and allow short-distance transportation between 15°C and 30°C.
2. It should be placed out of reach of children.